Jonathan Reynolds has returned as the United Kingdom’s business secretary amid significant departmental restructuring under the leadership of Andy Burnham. The Department for Science, Innovation & Technology has been dissolved, with its functions integrated into an expanded Department for Business & Trade. This reorganization has sparked concern across the scientific and life sciences communities, particularly following the departure of Lord Vallance of Balham as science minister.
Lord Vallance, who stepped down from his ministerial role for personal reasons after nearly a decade in government, was widely regarded for his expertise and commitment to the life sciences sector. Prior to his ministerial roles, Vallance served as the government’s chief scientific adviser from 2018 to 2023 and held the position of president of research and development at pharmaceutical company GSK. His departure has been met with disappointment by industry leaders, who valued his experience in both science and business.
During his tenure, Vallance played a pivotal role in improving the commercial climate for life sciences in the UK, helping to launch the Health Data Research Service aimed at enhancing access to NHS data for medical research. Prominent organizations including the Francis Crick Institute, the Wellcome Trust, and the Association of the British Pharmaceutical Industry (ABPI) acknowledged his contributions. Richard Torbett, ABPI’s chief executive, described Vallance as “instrumental in beginning to turn around international sentiment towards the UK as a life sciences destination,” while Chris Hollowood, CEO of life sciences investment firm Syncona, praised him for effectively bridging government, industry, and scientific communities.
Despite widespread appreciation for Vallance, there remains uncertainty over how scientific responsibilities will be managed within the new business-oriented department. Industry stakeholders are seeking clearer guidance from Whitehall to understand how science and innovation will be prioritized going forward. One senior investor expressed concern about the loss of a dedicated science minister, emphasizing the importance of having a government champion for science, particularly if the UK aims to maintain its aspiration of becoming a “scientific superpower.”
There is also ongoing pressure on the government to uphold a recent agreement reached under Sir Keir Starmer’s administration, which committed to doubling spending on innovative medicines over ten years in return for a three-year tariff exemption on pharmaceutical exports to the United States. Industry sources have warned that any reversal could damage the UK’s international reputation for life sciences investment.
Reynolds, who has previously served as business secretary, is viewed by many as a positive appointment despite mixed reviews of the broader government approach to business costs. His first 14-month tenure saw him oversee the launch of the UK’s industrial strategy, advocate for a regulator focus on economic growth, and approve major corporate takeovers, such as the parent company of Royal Mail. With strong ties to northern England, Reynolds now faces the challenge of rebuilding relationships with businesses dealing with regulatory and financial pressures, alongside addressing uncertainties surrounding companies like Thames Water.
An urgent question was raised in the House of Lords concerning the government’s impact assessment on the abolition of the Department for Science, Innovation & Technology, reflecting ongoing parliamentary scrutiny of the recent structural changes and their potential implications for UK science and innovation policy.